deltatrials
Terminated PHASE2 NCT01640730

Safety and Exploratory Efficacy of Kanglaite Injection in Non Small Cell Lung Cancer

An Open Label Safety and Exploratory Efficacy Study of Kanglaite Injection in Patients Having Progressive Stage IV NSCLC Who Are Not Candidates for Other Anti-cancer Treatment

Sponsor: KangLaiTe USA

Conditions Stage IV NSCLC
Interventions Kanglaite Injection
Updated 6 times since 2017 Last updated: Jan 15, 2014 Started: May 31, 2012 Primary completion: Oct 31, 2012 Completion: Oct 31, 2012

This PHASE2 trial investigates Stage IV NSCLC and is currently terminated or withdrawn. KangLaiTe USA leads this study, which shows 6 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Change History

6 versions recorded

  1. Sep 2024 — Present [monthly]

    Terminated PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  3. Jan 2021 — Jul 2024 [monthly]

    Terminated PHASE2

  4. Jun 2018 — Jan 2021 [monthly]

    Terminated PHASE2

  5. Feb 2017 — Jun 2018 [monthly]

    Terminated PHASE2

▶ Show 1 earlier version

  1. Jan 2017 — Feb 2017 [monthly]

    Terminated PHASE2

    First recorded

May 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • KangLaiTe USA
Data source: KangLaiTe USA

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Memphis, United States